Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics.

Currently, removal of core fucose from the Fc oligosaccharides of therapeutic antibodies is widely recognized as being of great importance for the effector function of antibody-dependent cellular cytotoxicity, and alpha-1,6-fucosyltransferase (FUT8) knockout cells have been generated as an ideal host cell line for manufacturing such therapeutics. Here, we attempted to identify genes other than FUT8 that could be targeted for the manufacture of non-fucosylated therapeutics. Loss-of-function analyses using siRNAs against three key genes involved in oligosaccharide fucosylation in Chinese hamster ovary (CHO) cells revealed that there was a positive correlation between the Fc oligosaccharide fucosylation and the mRNA expression through the origin in the cases of both GDP-fucose 4,6-dehydratase (GMD) and FUT8, but not for the GDP-fucose transporter, suggesting that there is no functional redundancy in GMD and FUT8. GMD knockout CHO/DG44 cells were successfully established, and were confirmed to be devoid of intracellular GDP-fucose and to produce completely non-fucosylated antibodies. GMD knockout cells recovered their fucosylation capability through the salvage pathway upon addition of l-fucose into the culture medium, and exhibited equable morphology, growth kinetics and recombinant protein productivity, demonstrating that loss of oligosaccharide fucosylation has no impact on these cellular phenotypes. Our results demonstrate that GMD knockout is a new strategy applicable to the manufacture of non-fucosylated therapeutic antibodies, and completely O-fucose-negative therapeutics as well.

[1]  Kazuya Yamano,et al.  Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. , 2004, Biotechnology and bioengineering.

[2]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[3]  Samuel Moser,et al.  Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II , 2006, Biotechnology and bioengineering.

[4]  C. Rogers,et al.  Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus , 2002, The Journal of cell biology.

[5]  L. Chasin,et al.  Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Elbein,et al.  GDP-l-fucose Pyrophosphorylase , 1998, The Journal of Biological Chemistry.

[7]  F. Wurm.  Production of recombinant protein therapeutics in cultivated mammalian cells , 2004, Nature Biotechnology.

[8]  S. Iida,et al.  Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.

[9]  S. Masuda,et al.  The role of carbohydrate in recombinant human erythropoietin. , 1990, European journal of biochemistry.

[10]  J. Lowe,et al.  Fucose: biosynthesis and biological function in mammals. , 2003, Glycobiology.

[11]  Leonard G Presta,et al.  Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. , 2006, Advanced drug delivery reviews.

[12]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[13]  P. Stanley,et al.  Selection and characterization of eight phenotypically distinct lines of lectin-resistant chinese hamster ovary cells , 1975, Cell.

[14]  P. H. Atkinson,et al.  Fucosyl-glycoprotein and precursor polls in HeLa cells. , 1975, Biochemistry.

[15]  K. Shitara,et al.  Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. , 2000, Molecular immunology.

[16]  M. Reitman,et al.  Mouse lymphoma cell lines resistant to pea lectin are defective in fucose metabolism. , 1980, The Journal of biological chemistry.

[17]  K. Shitara,et al.  Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma , 2004, Cancer Research.

[18]  C. Hirschberg.  Golgi nucleotide sugar transport and leukocyte adhesion deficiency II. , 2001, The Journal of clinical investigation.

[19]  Shinji Hosoi,et al.  Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC , 2006, Biotechnology and bioengineering.

[20]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[21]  A. Orellana,et al.  Nucleotide-sugar transporters: structure, function and roles in vivo. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[22]  P. Stanley,et al.  Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose. , 1986, Archives of biochemistry and biophysics.

[23]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[24]  S. Ménard,et al.  Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.

[25]  L. Sturla,et al.  Synthesis of GDP-L-fucose by the Human FX Protein* , 1996, The Journal of Biological Chemistry.

[26]  Akira Okazaki,et al.  Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.

[27]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[28]  J. R. Somoza,et al.  Structural and kinetic analysis of Escherichia coli GDP-mannose 4,6 dehydratase provides insights into the enzyme's catalytic mechanism and regulation by GDP-fucose. , 2000, Structure.

[29]  alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells. , 1994, The Journal of clinical investigation.

[30]  A. Mulichak,et al.  Crystal structure of a tetrameric GDP‐d‐mannose 4,6‐dehydratase from a bacterial GDP‐d‐rhamnose biosynthetic pathway , 2004, Protein science : a publication of the Protein Society.